High purity phentolamine mesylate and method for making same

Abstract

The present invention provides a method for synthesizing phentolamine mesylate from phentolamine and methanesulfonic acid in the presence of acetone and water.The method of the present invention provides high-purity phentolamine mesylate.The present invention also provides high-purity phentolamine mesylate.The present invention further provides a method for inhibiting iris smooth muscle contraction, comprising administering an effective amount of a compound of the present invention to a subject in need thereof.The present invention further provides a method for decreasing pupil diameter, comprising administering an effective amount of a compound of the present invention to a subject in need thereof.

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Application No. 63 / 189,839, filed May 18, 2021, and Chinese Application No. 202110679032.9, filed June 18, 2021, the disclosures of each of which are incorporated by reference in their entireties herein.

[0002] FIELD OF THEINVENTION The present invention provides a method for synthesizing phentolamine mesylate from phentolamine and methanesulfonic acid in the presence of acetone and water. The method of the present invention provides high purity phentolamine mesylate. The present invention also provides high purity phentolamine mesylate. [Background technology]

[0003] 2. Background of the Invention Phentolamine mesylate is a nonselective alpha adrenergic receptor antagonist approved by the U.S. Food and Drug Administration (FDA) for use in reversing soft tissue anesthesia. Phentolamine mesylate has also been approved by the FDA for use in preventing or controlling hypertensive episodes in patients with pheochromocytoma and for the treatment of skin necrosis following intravenous administration or extravasation of norepinephrine.

[0004] Phentolamine mesylate continues to be investigated for new indications. Therefore, improved syntheses of phentolamine to produce a high purity product are desirable. Summary of the Invention [Means for solving the problem]

[0005] Summary of the Invention The present invention provides a method for making phentolamine mesylate, comprising the steps of:

[0006] (a) Compound 1 [ka] with methanesulfonic acid, in the presence of acetone and water, under conditions effective to produce a first mixture comprising phentolamine mesylate;

[0007] (b) combining the first mixture with methyl t-butyl ether to form a second mixture; and

[0008] (c) precipitating phentolamine mesylate from the second mixture (each method is a "synthetic method of the invention").

[0009] The present invention further provides phentolamine mesylate made by the synthetic method of the present invention, having a purity obtainable by the synthetic method of the present invention, or exhibiting an X-ray powder diffraction (XRPD) pattern obtainable by the synthetic method of the present invention (phentolamine mesylate is a "compound of the present invention").

[0010] The present invention further provides phentolamine mesylate, which exhibits an XRPD pattern including a peak at about 6.87±0.2 degrees 2θ, a peak at about 20.32±0.2 degrees 2θ, and a peak at about 21.36±0.2 degrees 2θ.

[0011] The present invention further provides compositions comprising an effective amount of a compound of the present invention (each composition is a "Composition of the Invention").

[0012] The present invention further provides a method of inhibiting contraction of smooth muscle of the iris, comprising administering to a subject in need thereof an effective amount of a compound of the present invention.

[0013] The present invention further provides a method for decreasing pupil diameter, comprising administering to a subject in need thereof an effective amount of a compound of the present invention.

[0014] The present invention further provides a method for improving visual contrast sensitivity or visual acuity, comprising administering to a subject in need thereof an effective amount of a compound of the present invention.

[0015] The present invention further provides a method of treating impaired dark vision or night vision, comprising administering to a subject in need thereof an effective amount of a compound of the present invention.

[0016] The present invention further provides a method of treating or reversing pharmacologically induced mydriasis, comprising administering to a subject in need thereof an effective amount of a compound of the present invention.

[0017] The present invention further provides a method of treating presbyopia, comprising administering to a subject in need thereof an effective amount of a compound of the present invention.

[0018] Each method for inhibiting iris smooth muscle contraction, decreasing pupil diameter, improving visual contrast sensitivity or acuity, treating impaired dark or night vision, treating or reversing pharmacologically induced mydriasis, or treating presbyopia is a "therapeutic method of the invention." [Brief description of the drawings]

[0019] [Figure 1] FIG. 1 shows the XRPD pattern of phentolamine mesylate obtained as described in Example 2.

[0020] [Diagram 2] FIG. 2 shows the overlay of the thermogravimetric (TG) and differential scanning calorimetry (DSC) thermograms of phentolamine mesylate obtained as described in Example 2.

[0021] [Diagram 3] FIG. 3 shows the XRPD pattern of the United States Pharmacopeia (USP) reference standard of phentolamine mesylate.

[0022] [Figure 4] FIG. 4 shows the overlay of the TG thermogram of phentolamine mesylate USP reference standard with the DSC thermogram of phentolamine mesylate USP reference standard. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0023] Detailed Description of the Invention definition

[0024] The term "about" immediately preceding a numerical value means up to ±20% of that numerical value. For example, "about" a numerical value means ±up to 20%, in some embodiments ±up to 19%, ±up to 18%, ±up to 17%, ±up to 16%, ±up to 15%, ±up to 14%, ±up to 13%, ±up to 12%, ±up to 11%, ±up to 10%, ±up to 9%, ±up to 8%, ±up to 7%, ±up to 6%, ±up to 5%, ±up to 4%, ±up to 3%, ±up to 2%, ±up to 1%, ±less than ±up to 1%, or any other value or range of values ​​therein.

[0025] Throughout this specification, numerical ranges are provided for specific quantities. These ranges include all subranges therein. Thus, the range "50-80" includes all possible ranges therein (e.g., 51-79, 52-78, 53-77, 54-76, 55-75, 60-70, etc.). Furthermore, all values ​​within a given range may be endpoints of the range encompassed thereby (e.g., the range 50-80 includes ranges having endpoints such as 55-80, 50-75, etc.).

[0026] The term "pharmaceutically acceptable salt" includes both acid addition salts and base addition salts. Pharmaceutically acceptable salts can be obtained by reacting the compounds of the present invention, which function as bases, with inorganic or organic acids to form salts, such as hydrochloric acid, sulfuric acid, phosphoric acid, methanesulfonic acid, camphorsulfonic acid, oxalic acid, maleic acid, succinic acid, citric acid, formic acid, hydrobromic acid, benzoic acid, tartaric acid, fumaric acid, salicylic acid, mandelic acid, carbonic acid salts, and the like. Pharmaceutically acceptable salts can also be obtained by reacting the compounds of the present invention, which function as acids, with inorganic or organic bases to form salts, such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, ammonia, isopropylamine, trimethylamine salts, and the like. In some embodiments, the pharmaceutically acceptable salt is a zinc salt. Those skilled in the art will further recognize that pharmaceutically acceptable salts can be prepared by reacting the compounds of the present invention with a suitable inorganic or organic acid or base by any of several known methods.

[0027] The term "solvate" refers to a solvate complex. A solvate may be formed by solvation (the combination of a solvent molecule with a molecule or ion of a compound of the present invention), or the solvate may be an aggregate that includes a solute ion or molecule or a solvent molecule. The solvent may be water, in which case the solvate is a hydrate. Examples of hydrates include, but are not limited to, hemihydrate, monohydrate, dihydrate, trihydrate, hexahydrate, and the like. A solvate may be formed by hydration, including through the absorption of water. A pharmaceutically acceptable salt may also be a solvate. When the solvate is obtained by crystallization from a solvent, the solvent may be an alcohol, such as methanol or ethanol; an aldehyde; a ketone, such as acetone; or an ester, such as ethyl acetate.

[0028] The term "effective amount" refers to an amount of a compound of the invention effective to inhibit contraction of iris smooth muscle, decrease pupil diameter, improve visual contrast sensitivity or visual acuity, treat impaired dark or night vision, or treat or reverse pharmacologically induced mydriasis in a subject in need thereof.

[0029] All weight percentages referred to herein (i.e., "% by weight" and "wt.%" and w / w) are based on the total weight of the mixture or composition, as the case may be, unless otherwise specified.

[0030] As used herein, an "impurity" is a compound or substance other than phentolamine mesylate.

[0031] As used herein, "isolated" means isolated from a chemical synthesis reaction mixture. In some embodiments, the isolated phentolamine mesylate is at least 95% pure and contains 5% or less of one or more impurities. "At least x% pure" means that the compound of the present invention contains (100-x)% or less of one or more impurities. In some embodiments, the isolated phentolamine mesylate is at least 96%, at least 97%, at least 98%, or at least 99% pure and contains 4% or less, 3% or less, 2% or less, or 1% or less of impurities, respectively. In some embodiments, if present, the one or more impurities are present in the phentolamine mesylate as a weight percent. In some embodiments, if present, the one or more impurities are present in the phentolamine mesylate as a mole percent. In some embodiments, if present, the one or more impurities are present in the phentolamine mesylate as a volume percent.

[0032] As used herein, "substantially the same" when used in reference to an XRPD pattern means that each peak in the XRPD pattern differs from the respective peak of the reference compound by no more than ±0.2 degrees 2θ, and in some embodiments no more than ±0.1 degrees 2θ.

[0033] As used herein, "substantially the same" when used in reference to a DSC thermogram means that each peak in the DSC thermogram differs from the respective peak of the reference compound by no more than ±3°C, and in some embodiments no more than ±2°C.

[0034] As used herein, "substantially the same" when used in relation to a TG thermogram means that each peak in the TG thermogram differs from the respective peak of the reference compound referenced by no more than ±3°C, and in some embodiments no more than ±2°C.

[0035] The synthetic method of the present invention

[0036] The present invention provides a method for making phentolamine mesylate, comprising the steps of:

[0037] (a) Compound 1 [ka] with methanesulfonic acid, in the presence of acetone and water, under conditions effective to produce a first mixture comprising phentolamine mesylate;

[0038] (b) combining the first mixture with methyl t-butyl ether to form a second mixture; and

[0039] (c) precipitating phentolamine mesylate from the second mixture.

[0040] In some embodiments of the synthesis method of the present invention, the method further comprises (d) isolating phentolamine mesylate from the second mixture, and the isolating step provides isolated phentolamine mesylate.In some embodiments, the isolating step is a filtering step, and the isolated phentolamine mesylate is filtered phentolamine mesylate.In some embodiments, the filtered phentolamine mesylate is washed with methyl t-butyl ether.

[0041] In some embodiments of the synthesis method of the present invention, the method further comprises the step of (e) drying the isolated phentolamine mesylate to provide dried phentolamine mesylate. In some embodiments, the isolated phentolamine or filtered phentolamine is dried using a rotary evaporator. In some embodiments, the isolated phentolamine or filtered phentolamine is dried using a rotary evaporator at a temperature of about 30° C. to about 50° C. In some embodiments, the isolated phentolamine or filtered phentolamine is dried using a rotary evaporator at a temperature of about 30° C. to about 40° C. In some embodiments, the drying comprises lyophilization. In some embodiments, the drying comprises drying using a rotary evaporator followed by lyophilization. In some embodiments, the drying is continued until the loss on drying is 0.5% or less of the weight of the isolated phentolamine mesylate subjected to drying.

[0042] In some embodiments, the drying is performed at a pressure ranging from about 0.001 mbar to about 1000 mbar. In some embodiments, the drying is performed at a pressure ranging from about 1 mbar to about 1000 mbar. In some embodiments, the drying is performed at a pressure ranging from about 1 mbar to about 500 mbar. In some embodiments, the drying is performed at a pressure ranging from about 1 mbar to about 200 mbar. In some embodiments, the drying is performed at a pressure ranging from about 1 mbar to about 100 mbar. In some embodiments, the drying is performed at a pressure ranging from about 1 mbar to about 50 mbar. In some embodiments, the drying is performed at a pressure ranging from about 0.001 mbar to about 1 mbar. In some embodiments, the drying is performed at a pressure ranging from about 0.001 mbar to about 0.75 mbar. In some embodiments, the drying is performed at a pressure ranging from about 0.001 mbar to about 0.5 mbar. In some embodiments, the drying is performed at a pressure ranging from about 0.005 mbar to about 0.75 mbar. In some embodiments, drying is performed at a pressure ranging from about 0.01 mbar to about 0.75 mbar. In some embodiments, drying is performed at a pressure ranging from about 0.05 mbar to about 0.75 mbar. In some embodiments, drying is performed at a pressure ranging from about 0.05 mbar to about 0.5 mbar. In some embodiments, drying is performed at a pressure of about 40 mbar.

[0043] In some embodiments, the lyophilization is performed at a temperature of about -78°C to about 0°C. In some embodiments, the lyophilization is performed at a temperature of about -50°C to about 0°C. In some embodiments, the lyophilization is performed at a temperature of about -50°C to about -10°C. In some embodiments, the lyophilization is performed at a temperature of about 0°C, about -5°C, about -10°C, about -15°C, about -20°C, about -25°C, about -30°C, about -35°C, about -40°C, about -45°C, about -50°C, about -55°C, about -60°C, about -65°C, about -70°C, about -75°C, or about -78°C. In some embodiments, the temperature is the temperature inside the container containing phentolamine mesylate. In some embodiments, the temperature is the temperature outside the container containing phentolamine mesylate. In some embodiments, the temperature is the temperature of a cooling bath or the temperature inside a cooling jacket or freezer.

[0044] In some embodiments, the lyophilization is performed at a pressure ranging from about 0.001 mbar to about 1000 mbar. In some embodiments, the lyophilization is performed at a pressure ranging from about 1 mbar to about 1000 mbar. In some embodiments, the lyophilization is performed at a pressure ranging from about 1 mbar to about 500 mbar. In some embodiments, the lyophilization is performed at a pressure ranging from about 1 mbar to about 200 mbar. In some embodiments, the lyophilization is performed at a pressure ranging from about 1 mbar to about 100 mbar. In some embodiments, the lyophilization is performed at a pressure ranging from about 1 mbar to about 50 mbar. In some embodiments, the lyophilization is performed at a pressure ranging from about 0.001 mbar to about 1 mbar. In some embodiments, the lyophilization is performed at a pressure ranging from about 0.001 mbar to about 0.75 mbar. In some embodiments, the lyophilization is performed at a pressure ranging from about 0.001 mbar to about 0.5 mbar. In some embodiments, lyophilization is performed at a pressure ranging from about 0.005 mbar to about 0.75 mbar. In some embodiments, lyophilization is performed at a pressure ranging from about 0.01 mbar to about 0.75 mbar. In some embodiments, lyophilization is performed at a pressure ranging from about 0.05 mbar to about 0.75 mbar. In some embodiments, lyophilization is performed at a pressure ranging from about 0.05 mbar to about 0.5 mbar. In some embodiments, lyophilization is performed at a pressure of about 40 mbar.

[0045] In some embodiments, the freeze-drying is performed at a pressure ranging from about 50 mTorr to about 400 mTorr. In some embodiments, the freeze-drying is performed at a pressure ranging from about 100 mTorr to about 350 mTorr. In some embodiments, the freeze-drying is performed at a pressure ranging from about 100 mTorr to about 300 mTorr. In some embodiments, the freeze-drying is performed at a pressure ranging from about 100 mTorr to about 200 mTorr. In some embodiments, the freeze-drying is performed at a pressure of about 50 mTorr, about 75 mTorr, about 100 mTorr, about 125 mTorr, about 150 mTorr, about 175 mTorr, about 200 mTorr, about 225 mTorr, about 250 mTorr, about 275 mTorr, about 300 mTorr, about 325 mTorr, about 350 mTorr, about 375 mTorr, or about 400 mTorr.

[0046] In some embodiments, lyophilization is performed for about 30 minutes to about 7 days. In some embodiments, lyophilization is performed for about 30 minutes to about 5 days. In some embodiments, lyophilization is performed for about 30 minutes to about 3 days. In some embodiments, lyophilization is performed for about 30 minutes to about 24 hours. In some embodiments, lyophilization is performed for about 30 minutes to about 12 hours. In some embodiments, lyophilization is performed for about 30 minutes to about 6 hours. In some embodiments, lyophilization is performed for about 30 minutes to about 3 hours. In some embodiments, lyophilization is performed for about 30 minutes, about 45 minutes, about 60 minutes, about 75 minutes, about 90 minutes, about 105 minutes, about 120 minutes, about 135 minutes, about 150 minutes, about 165 minutes, or about 180 minutes. In some embodiments, lyophilization is performed for about 30 minutes, about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, about 24 hours, about 26 hours, about 28 hours, about 30 hours, about 32 hours, about 34 hours, about 36 hours, about 38 hours, about 40 hours, about 42 hours, about 44 hours, about 46 hours, about 48 hours, about 50 hours, about 52 hours, about 54 hours, about 56 hours, about 58 hours, about 60 hours, about 62 hours, about 64 hours, about 66 hours, about 68 hours, about 70 hours, or about 72 hours. In some embodiments, the times described herein for lyophilization are for one or more lyophilization cycles. In one embodiment, lyophilization is performed using 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 lyophilization cycles. In one embodiment, lyophilization includes an annealing step.

[0047] In some embodiments, lyophilization is performed with agitation. In some embodiments, lyophilization is performed without agitation.

[0048] In some embodiments of the synthetic methods of the invention, the ratio of acetone to water is about 5:1 acetone:water by volume to about 15:1 acetone:water by volume. In some embodiments, the ratio of acetone to water is about 10:1 acetone:water by volume to about 12:1 acetone:water by volume. In some embodiments, the ratio of acetone to water is about 11:1 acetone:water by volume. In some embodiments, the ratio of acetone to water is about 5:1, about 6:1, about 7:1, about 8:1, about 9:1, about 10:1, about 11:1, about 12:1, about 13:1, about 14:1, or about 15:1 acetone:water by volume.

[0049] In some embodiments of the synthesis method of the present invention, the concentration of compound 1 is about 0.2 moles / liter of acetone and water to about 0.4 moles / liter of acetone and water. In some embodiments, the concentration of compound 1 is about 0.3 moles / liter of acetone and water. In some embodiments, the concentration of compound 1 is about 0.2 moles / liter, about 0.25 moles / liter, about 0.3 moles / liter, about 0.35 moles / liter, or about 0.4 moles / liter of acetone and water.

[0050] In some embodiments of the synthesis method of the present invention, the acetone and water do not contain detectable amounts of alcohol solvent. In some embodiments of the synthesis method of the present invention, the acetone and water contain less than about 1%, less than about 0.5%, less than about 0.1%, or less than about 0.01% alcohol solvent by weight of the acetone and water. In some embodiments of the synthesis method of the present invention, the first mixture does not contain detectable amounts of alcohol solvent. In some embodiments of the synthesis method of the present invention, the first mixture contains less than about 1%, less than about 0.5%, less than about 0.1%, or less than about 0.01% alcohol solvent by weight of the first mixture. In some embodiments of the synthesis method of the present invention, the second mixture does not contain detectable amounts of alcohol solvent. In some embodiments of the synthesis method of the present invention, the second mixture contains less than about 1%, less than about 0.5%, less than about 0.1%, or less than about 0.01% alcohol solvent by weight of the second mixture. In some embodiments of the synthesis method of the present invention, the acetone and water, the first mixture, and the second mixture do not contain detectable amounts of alcohol solvent. In some embodiments, the synthesis method of the present invention is carried out in the absence of detectable amounts of alcohol solvent.In some embodiments of the synthesis method of the present invention, acetone and water, the first mixture and the second mixture contain less than about 1%, less than about 0.5%, less than about 0.1%, or less than about 0.01% of alcohol solvent by weight of acetone and water, the first mixture, or the second mixture.In some embodiments, the synthesis method of the present invention is carried out in the absence of detectable amounts of alcohol solvent.In some embodiments, the alcohol solvent is isopropanol, n-propanol, ethanol, or methanol.

[0051] In some embodiments of the synthesis method of the present invention, the acetone and water do not contain toluene. In some embodiments of the synthesis method of the present invention, the first mixture does not contain toluene. In some embodiments of the synthesis method of the present invention, the second mixture does not contain toluene. In some embodiments of the synthesis method of the present invention, the acetone and water, the first mixture and the second mixture do not contain toluene. In some embodiments, the synthesis method of the present invention is carried out in the absence of detectable amounts of toluene. In some embodiments, the synthesis method of the present invention is carried out in the absence of detectable amounts of alcohol solvents and toluene.

[0052] In some embodiments of the synthetic methods of the invention, the acetone and water are at or are adjusted to a temperature of about 15° C. to about 25° C. In some embodiments, the acetone and water are at or are adjusted to a temperature of about 15° C. to about 25° C. immediately prior to reacting compound 1 with methanesulfonic acid.

[0053] In some embodiments of the synthesis method of the present invention, compound 1, acetone, and water form a solution, and methanesulfonic acid is added to the solution. In some embodiments, compound 1, acetone, and water form a solution, and methanesulfonic acid is added dropwise to the solution. In some embodiments, compound 1, acetone, and water form a solution, and methanesulfonic acid is added to the solution, and the addition of methanesulfonic acid increases the temperature of the solution to about 40°C to about 50°C. In some embodiments, compound 1, acetone, and water form a solution, and methanesulfonic acid is added to the solution, and the first mixture is stirred for about 30 minutes after complete addition of methanesulfonic acid. In some embodiments, compound 1, acetone, and water form a solution, and methanesulfonic acid is added to the solution, and the first mixture is stirred for at least about 30 minutes after complete addition of methanesulfonic acid.

[0054] In some embodiments of the synthesis method of the present invention, compound 1, acetone, and water form a solution, and the solution is added to methanesulfonic acid. In some embodiments, compound 1, acetone, and water form a solution, and the solution is added dropwise to methanesulfonic acid. In some embodiments, compound 1, acetone, and water form a solution, and the solution is added to methanesulfonic acid, and the addition of the solution increases the temperature of the solution to about 40°C to about 50°C. In some embodiments, compound 1, acetone, and water form a solution, and the solution is added to methanesulfonic acid, and after complete addition of the solution, the first mixture is stirred for about 30 minutes. In some embodiments, compound 1, acetone, and water form a solution, and the solution is added to methanesulfonic acid, and after complete addition of the solution, the first mixture is stirred for at least about 30 minutes.

[0055] In some embodiments of the synthesis method of the present invention, compound 1, acetone, and water form a suspension, and methanesulfonic acid is added to the suspension. In some embodiments, compound 1, acetone, and water form a suspension, and methanesulfonic acid is added dropwise to the suspension. In some embodiments, compound 1, acetone, and water form a suspension, and methanesulfonic acid is added to the suspension, and the addition of methanesulfonic acid increases the temperature of the suspension to about 40°C to about 50°C. In some embodiments, compound 1, acetone, and water form a suspension, and methanesulfonic acid is added to the suspension, and the first mixture is stirred for about 30 minutes after complete addition of methanesulfonic acid. In some embodiments, compound 1, acetone, and water form a suspension, and methanesulfonic acid is added to the suspension, and the first mixture is stirred for at least about 30 minutes after complete addition of methanesulfonic acid.

[0056] In some embodiments of the synthesis method of the present invention, compound 1, acetone, and water form a suspension, and the suspension is added to methanesulfonic acid. In some embodiments, compound 1, acetone, and water form a suspension, and the suspension is added dropwise to methanesulfonic acid. In some embodiments, compound 1, acetone, and water form a suspension, and the suspension is added to methanesulfonic acid, and the addition of the suspension increases the temperature of the suspension to about 40°C to about 50°C. In some embodiments, compound 1, acetone, and water form a suspension, and the suspension is added to methanesulfonic acid, and the first mixture is stirred for about 30 minutes after complete addition of the suspension. In some embodiments, compound 1, acetone, and water form a suspension, and the suspension is added to methanesulfonic acid, and the first mixture is stirred for at least about 30 minutes after complete addition of the suspension.

[0057] In some embodiments of the synthesis method of the present invention, the first mixture is transparent. In this context, "transparent" means that all visible solids are completely dissolved or are no longer visible. In some embodiments, the first mixture is heated at about 45° C. and stirred until the first mixture is transparent. In some embodiments, the first mixture is heated at about 45° C. and stirred at about 45° C. until the first mixture is transparent.

[0058] In some embodiments of the synthetic method of the invention, the method comprises reacting 1 molar equivalent of compound 1 with about 0.9 molar equivalents to about 1.5 molar equivalents of methanesulfonic acid. In some embodiments, the synthetic method comprises reacting 1 molar equivalent of compound 1 with about 1.1 molar equivalents of methanesulfonic acid. In some embodiments, the synthetic method comprises reacting 1 molar equivalent of compound 1 with about 0.9 molar equivalents, about 1.0 molar equivalents, about 1.1 molar equivalents, about 1.2 molar equivalents, about 1.3 molar equivalents, about 1.4 molar equivalents, or about 1.5 molar equivalents of methanesulfonic acid.

[0059] In some embodiments, the mixing comprises adding methyl t-butyl ether to the first mixture. In some embodiments, the mixing comprises adding the first mixture to methyl t-butyl ether.

[0060] In some embodiments of the synthetic methods of the invention, the first mixture is at or adjusted to a temperature of about 15° C. to about 25° C. immediately prior to combining the first mixture with methyl t-butyl ether.

[0061] In some embodiments of the synthesis method of the present invention, precipitating phentolamine mesylate from the second mixture comprises cooling the second mixture to a temperature of about 15° C. to about −25° C. In some embodiments, precipitating phentolamine mesylate from the second mixture comprises cooling the second mixture to a temperature of about 15° C. to about −15° C. In some embodiments, precipitating phentolamine mesylate from the second mixture comprises cooling the second mixture to a temperature of about 5° C. to about −25° C. In some embodiments, precipitating phentolamine mesylate from the second mixture comprises cooling the second mixture to a temperature of about 5° C. to about −15° C. In some embodiments, precipitating phentolamine mesylate from the second mixture comprises cooling the second mixture to a temperature of about 15° C. to about 8° C. In some embodiments, precipitating phentolamine mesylate from the second mixture comprises cooling the second mixture to a temperature of about 14° C. to about 5° C. In some embodiments, precipitating phentolamine mesylate from the second mixture comprises cooling the second mixture to a temperature of about 0° C. to about −15° C. In some embodiments, precipitating phentolamine mesylate from the second mixture comprises cooling the second mixture to a temperature of about 3° C. to about −3° C. In some embodiments, precipitating phentolamine mesylate from the second mixture comprises cooling the second mixture to a temperature of about 0° C. In some embodiments, precipitating phentolamine mesylate from the second mixture comprises cooling the methyl t-butyl ether diluted mixture to a temperature of about −20° C.

[0062] In some embodiments of the synthetic method of the present invention, precipitating phentolamine mesylate comprises cooling the second mixture to a first temperature of about 15° C. to about −15° C., stirring the second mixture at the first temperature for about 1 hour, and then further cooling the second mixture to a second temperature of about −20° C. In some embodiments, the first temperature is about 15° C. to about −5° C. In some embodiments, the first temperature is about 15° C. to about 0° C. In some embodiments, the first temperature is about 14° C. to about 8° C. In some embodiments, the first temperature is about 3° C. to about −3° C.

[0063] In some embodiments, the second mixture is cooled to the first temperature at an average rate of about 0.5° C. / min to about 2° C. / min. In some embodiments, the second mixture is cooled to the first temperature at an average rate of about 1° C. / min to about 1.5° C. / min. In some embodiments, the second mixture is cooled to the first temperature at an average rate of about 1.33° C. / min. In some embodiments, it takes about 5 minutes to about 60 minutes to cool the second mixture to the first temperature. In some embodiments, it takes about 10 minutes to about 45 minutes to cool the second mixture to the first temperature. In some embodiments, it takes about 10 minutes to about 30 minutes to cool the second mixture to the first temperature. In some embodiments, it takes about 15 minutes to cool the second mixture to the first temperature.

[0064] In some embodiments, the second mixture is cooled from the first temperature to the second temperature at an average rate of about 0.5° C. / min to about 2° C. / min. In some embodiments, the second mixture is cooled from the first temperature to the second temperature at an average rate of about 0.75° C. / min to about 1.5° C. / min. In some embodiments, the second mixture is cooled from the first temperature to the second temperature at an average rate of about 1° C. / min. In some embodiments, it takes about 5 minutes to about 60 minutes to cool the second mixture from the first temperature to the second temperature. In some embodiments, it takes about 10 minutes to about 45 minutes to cool the second mixture from the first temperature to the second temperature. In some embodiments, it takes about 10 minutes to about 30 minutes to cool the second mixture from the first temperature to the second temperature. In some embodiments, it takes about 20 minutes to cool the second mixture from the first temperature to the second temperature.

[0065] In some embodiments of the synthesis method of the present invention, the method is carried out in the absence of detectable amounts of alkyl methanesulfonate.In some embodiments, the method does not produce alkyl methanesulfonate, for example as a by-product or decomposition product.In some embodiments, the compound of the present invention does not contain alkyl methanesulfonate.

[0066] In some embodiments, the purity of the methanesulfonic acid is at least about 95% (wt%), and the methanesulfonic acid contains about 5% or less (wt%) of impurities of methanesulfonic acid. In some embodiments, the purity of the methanesulfonic acid is at least about 97% (wt%), and the methanesulfonic acid contains about 3% or less (wt%) of impurities of methanesulfonic acid. In some embodiments, the purity of the methanesulfonic acid is at least about 98% (wt%), and the methanesulfonic acid contains about 2% or less (wt%) of impurities of methanesulfonic acid. In some embodiments, the purity of the methanesulfonic acid is at least about 99% (wt%), and the methanesulfonic acid contains about 1% or less (wt%) of impurities. In some embodiments, the methanesulfonic acid does not contain detectable amounts of alkyl methanesulfonates. In some embodiments, the impurities are determined by high performance liquid chromatography (HPLC). In some embodiments, the impurities are determined by gas chromatography (GC).

[0067] In some embodiments, the purity of the acetone is at least about 95% (wt%) and the acetone contains about 5% or less (wt%) of acetone impurities. In some embodiments, the purity of the acetone is at least about 97% (wt%) and the acetone contains about 3% or less (wt%) of acetone impurities. In some embodiments, the purity of the acetone is at least about 98% (wt%) and the acetone contains about 2% or less (wt%) of acetone impurities. In some embodiments, the purity of the acetone is at least about 99% (wt%) and the acetone contains about 1% or less (wt%) of acetone impurities. In some embodiments, the acetone does not contain detectable amounts of alkyl methanesulfonates. In some embodiments, the impurities are determined by high performance liquid chromatography (HPLC). In some embodiments, the impurities are determined by gas chromatography (GC).

[0068] In some embodiments, the purity of the water is at least about 95% (wt%) and the water contains about 5% or less (wt%) of impurities. In some embodiments, the purity of the water is at least about 97% (wt%) and the water contains about 3% or less (wt%) of impurities. In some embodiments, the purity of the water is at least about 98% (wt%) and the water contains about 2% or less (wt%) of impurities. In some embodiments, the purity of the water is at least about 99% (wt%) and the water contains about 1% or less (wt%) of impurities. In some embodiments, the water does not contain detectable amounts of alkyl methanesulfonates. In some embodiments, the impurities are determined by high performance liquid chromatography (HPLC).

[0069] In some embodiments, the purity of the methyl t-butyl ether is at least about 95% (wt%), and the methyl t-butyl ether contains about 5% or less of the impurities (wt%) of the methyl t-butyl ether. In some embodiments, the purity of the methyl t-butyl ether is at least about 97% (wt%), and the methyl t-butyl ether contains about 3% or less of the impurities (wt%) of the methyl t-butyl ether. In some embodiments, the purity of the methyl t-butyl ether is at least about 98% (wt%), and the methyl t-butyl ether contains about 2% or less of the impurities (wt%) of the methyl t-butyl ether. In some embodiments, the purity of the methyl t-butyl ether is at least about 99% (wt%), and the methyl t-butyl ether contains about 1% or less of the impurities (wt%) of the methyl t-butyl ether. In some embodiments, the methyl t-butyl ether does not contain detectable amounts of alkyl methanesulfonates. In some embodiments, the impurities are determined by high performance liquid chromatography (HPLC). In some embodiments, the impurities are determined by gas chromatography (GC).

[0070] In some embodiments, Compound 1 does not contain an impurity. In some embodiments, Compound 1 contains an impurity. In some embodiments, the impurity is an alkyl methanesulfonate. In some embodiments of the compounds of the present invention, the alkyl methanesulfonate is methyl methanesulfonate, ethyl methanesulfonate, n-propyl methanesulfonate, or isopropyl methanesulfonate. In some embodiments, the impurity is a process by-product or a degradation product. In some embodiments, the impurity is impurity A (N-(2-aminoethyl)-2-[(3-hydroxyphenyl)(4-methylphenyl)amino]-acetamide): [ka] .

[0071] In some embodiments, the impurity is a salt of impurity A. In some embodiments, the impurity is a methanesulfonate salt of impurity A. In some embodiments, impurity A is a by-product or a decomposition product.

[0072] In some embodiments, the impurity is impurity B (2-chloromethyl-4,5-dihydro-1H-imidazole): [ka] .

[0073] In some embodiments, impurity B is a process by-product. In some embodiments, the impurity is a salt of impurity B. In some embodiments, the impurity is a methanesulfonate salt of impurity B.

[0074] In some embodiments, the impurity is impurity C (3-hydroxy-4'-methyldiphenylamine): [ka] .

[0075] In some embodiments, impurity C is a process by-product or a degradation product. In some embodiments, impurity C is a degradation product. In some embodiments, the impurity is a salt of impurity C. In some embodiments, the impurity is a methanesulfonate salt of impurity C. In some embodiments, the impurity is one or more of impurity A, impurity B, and impurity C, or salts thereof. In some embodiments, the salt is a methanesulfonate salt.

[0076] In some embodiments, the purity of compound 1 is about 95.0%-100% by weight, and compound 1 contains 0%-about 5.0% impurities by weight of compound 1. In some embodiments, the purity of compound 1 is about 98%-100% by weight, and compound 1 contains 0%-about 2% impurities by weight of compound 1. In some embodiments, the purity of compound 1 is about 98%, about 98.5%, about 99%, about 99.5% or 100% by weight, and compound 1 contains about 2%, about 1.5%, about 1%, about 0.5% or 0% impurities by weight of compound 1, respectively. In some embodiments, the purity or impurities are determined by high performance liquid chromatography (HPLC). In some embodiments, the impurities are determined by titration.

[0077] In some embodiments, the purity of compound 1 is at least about 98% by weight as determined by GC, and compound 1 contains about 2% or less impurities by weight of compound 1. In some embodiments, the purity of compound 1 is about 95.0%-100% by weight as determined by GC, and compound 1 contains 0%-about 5.0% impurities by weight of compound 1. In some embodiments, the purity of compound 1 is about 98%-100% by weight as determined by GC, and compound 1 contains 0%-about 2% impurities by weight of compound 1. In some embodiments, the purity of compound 1 is about 98%, about 98.5%, about 99%, about 99.5% or 100% by weight as determined by GC, and compound 1 contains about 2%, about 1.5%, about 1%, about 0.5% or 0% impurities by weight of compound 1, respectively. In some embodiments, compound 1 contains less than about 0.5% solvent as determined by GC. In some embodiments, Compound 1 contains less than about 0.3% solvent as determined by GC.

[0078] In some embodiments, compound 1 contains less than 0.5% impurities by weight based on the weight of compound 1. In some embodiments, compound 1 contains less than 0.5% impurities by weight, less than 0.4% impurities by weight, less than 0.3% impurities by weight, less than 0.2% impurities by weight, or less than 0.1% impurities by weight of compound 1. In some embodiments, compound 1 contains 0.5% or less impurities by weight of compound 1. In some embodiments, compound 1 contains 0.5% or less impurities by weight, less than 0.4% impurities by weight, less than 0.3% impurities by weight, less than 0.2% impurities by weight, or less than 0.1% impurities by weight of compound 1. In some embodiments, the impurities are determined by high performance liquid chromatography (HPLC). In some embodiments, the impurities are determined by titration.

[0079] In some embodiments, the impurity in Compound 1 is an alkyl methanesulfonate. In some embodiments of the compounds of the present invention, the alkyl methanesulfonate is methyl methanesulfonate, ethyl methanesulfonate, n-propyl methanesulfonate, or isopropyl methanesulfonate.

[0080] In some embodiments, the impurity in Compound 1 is a process by-product or a degradation product.

[0081] In some embodiments, the impurity in Compound 1 is impurity A (N-(2-aminoethyl)-2-[(3-hydroxyphenyl)(4-methylphenyl)amino]-acetamide). In some embodiments, the impurity is a salt of impurity A. In some embodiments, the impurity is a methanesulfonate salt of impurity A.

[0082] In some embodiments, impurity A is a by-product or a decomposition product.

[0083] In some embodiments, the impurity in Compound 1 is impurity B (2-chloromethyl-4,5-dihydro-1H-imidazole). In some embodiments, impurity B is a process by-product. In some embodiments, the impurity is a salt of impurity B. In some embodiments, the impurity is a methanesulfonate salt of impurity B.

[0084] In some embodiments, the impurity in Compound 1 is impurity C (3-hydroxy-4'-methyldiphenylamine). In some embodiments, impurity C is a process by-product or a degradation product. In some embodiments, impurity C is a degradation product. In some embodiments, the impurity is a salt of impurity C. In some embodiments, the impurity is a methanesulfonate salt of impurity C.

[0085] In some embodiments, the impurity in Compound 1 is one or more of impurity A, impurity B, and impurity C, or a salt thereof. In some embodiments, the salt is a methanesulfonate salt.

[0086] In some embodiments, the impurity in Compound 1 is an alcohol solvent. In some embodiments, the alcohol solvent is methanol, ethanol, n-propanol, or isopropanol.

[0087] In some embodiments, the impurity in Compound 1 is toluene.

[0088] In some embodiments, the impurity in Compound 1 is acetone, ethyl acetate or methyl t-butyl ether. In some embodiments, the impurity is water. In some embodiments of the compounds of the present invention, the impurity is a solvent.

[0089] In some embodiments, the purity of the methanesulfonic acid is at least about 99% by weight, and the methanesulfonic acid contains about 1% or less impurities by weight of methanesulfonic acid. In some embodiments, the purity of the methanesulfonic acid is about 95.0%-100% by weight, and the methanesulfonic acid contains 0% to about 5.0% impurities by weight of methanesulfonic acid. In some embodiments, the purity of the methanesulfonic acid is about 98%-100% by weight, and the methanesulfonic acid contains 0% to about 2% impurities by weight of methanesulfonic acid. In some embodiments, the purity of the methanesulfonic acid is about 98%, about 98.5%, about 99%, about 99.5% or 100% by weight, and the methanesulfonic acid contains about 2%, about 1.5%, about 1%, about 0.5% or 0% impurities by weight of methanesulfonic acid, respectively. In some embodiments, purity or impurities are determined by high performance liquid chromatography (HPLC). In some embodiments, impurities are determined by titration.

[0090] In some embodiments, the purity of the methanesulfonic acid is at least about 99%, and the methanesulfonic acid contains about 1% or less impurities by chromatographic area of ​​the methanesulfonic acid peak as determined by GC. In some embodiments, the purity of the methanesulfonic acid is about 95.0%-100%, and contains 0% to about 5.0% impurities by chromatographic area of ​​the methanesulfonic acid peak as determined by GC. In some embodiments, the purity of the methanesulfonic acid is about 98%-100%, and the methanesulfonic acid contains 0% to about 2% impurities by chromatographic area of ​​the methanesulfonic acid peak as determined by GC. In some embodiments, the purity of compound 1 is about 98%, about 98.5%, about 99%, about 99.5% or 100%, and the methanesulfonic acid contains about 2%, about 1.5%, about 1%, about 0.5% or 0% impurities, respectively, by chromatographic area of ​​the methanesulfonic acid peak as determined by GC. In some embodiments, the methanesulfonic acid contains less than about 0.5% solvent as determined by GC. In some embodiments, the methanesulfonic acid contains less than about 0.3% solvent as determined by GC.

[0091] In some embodiments, the methanesulfonic acid contains less than 1% or less than 0.5% impurities by weight of methanesulfonic acid. In some embodiments, the methanesulfonic acid contains less than 1%, less than 0.9%, less than 0.8%, less than 0.7%, less than 0.6%, less than 0.5%, less than 0.4%, less than 0.3%, less than 0.2%, or less than 0.1% impurities by weight of methanesulfonic acid. In some embodiments, the methanesulfonic acid contains 1% or less or 0.5% or less impurities by weight of methanesulfonic acid. In some embodiments, the methanesulfonic acid contains 1% or less, less than 0.9%, less than 0.8%, less than 0.7%, less than 0.6%, less than 0.5%, less than 0.4%, less than 0.3%, less than 0.2%, or less than 0.1% impurities by weight of methanesulfonic acid. In some embodiments, the impurities are determined by high performance liquid chromatography (HPLC). In some embodiments, the impurities are determined by titration.

[0092] In some embodiments, the impurity in the methanesulfonic acid is an alkyl methanesulfonate. In some embodiments of the compounds of the present invention, the alkyl methanesulfonate is methyl methanesulfonate, ethyl methanesulfonate, n-propyl methanesulfonate, or isopropyl methanesulfonate.

[0093] In some embodiments, the impurity in the methanesulfonic acid is an alcohol solvent, hi some embodiments, the alcohol solvent is methanol, ethanol, n-propanol, or isopropanol.

[0094] In some embodiments, the impurity in the methanesulfonic acid is toluene.

[0095] In some embodiments, the impurity in the methanesulfonic acid is acetone, ethyl acetate or methyl t-butyl ether. In some embodiments, the impurity is water. In some embodiments of the compounds of the present invention, the impurity is a solvent.

[0096] In some embodiments, the method of the invention does not include subjecting the compound of the invention to further purification. In some embodiments, the method of the invention does not include further purification of the compound of the invention.

[0097] Compounds of the Invention

[0098] In some embodiments, the compound of the present invention is isolated phentolamine mesylate, filtered phentolamine mesylate or dried phentolamine mesylate.

[0099] In some embodiments, the compounds of the present invention are hygroscopic.

[0100] In some embodiments, the compounds of the present invention can be stored or stored under an inert gas. In some embodiments, the inert gas is argon. In some embodiments, the inert gas is nitrogen.

[0101] In some embodiments, the compounds of the present invention are hygroscopic and can be stored or stored under an inert gas, such as nitrogen or argon.

[0102] In some embodiments, the compounds of the invention are crystalline.

[0103] In some embodiments, the compounds of the present invention exhibit an X-ray powder diffraction (XRPD) pattern that includes a peak at about 6.87±0.2 degrees 2θ, a peak at about 20.32±0.2 degrees 2θ, and a peak at about 21.36±0.2 degrees 2θ. In some embodiments, the compounds of the present invention exhibit an XRPD pattern that further includes a peak at about 18.86±0.2 degrees 2θ and a peak at about 21.07±0.2 degrees 2θ. In some embodiments, the compounds of the present invention exhibit an XRPD pattern that further includes peaks at about 11.65±0.2 degrees 2θ, about 13.15±0.2 degrees 2θ, and about 20.85±0.2 degrees 2θ. In some embodiments, the compounds of the present invention exhibit an XRPD pattern that further includes a peak at about 20.05±0.2 degrees 2θ and a peak at about 23.87±0.2 degrees 2θ. In some embodiments, the compounds of the invention exhibit XRPD patterns that further include a peak at about 18.47±0.2 degrees 2θ and a peak at about 19.38±0.2 degrees 2θ. In some embodiments, the compounds of the invention exhibit XRPD patterns that further include a peak at about 14.71±0.2 degrees 2θ and a peak at about 22.22±0.2 degrees 2θ.

[0104] In some embodiments, the compounds of the present invention exhibit an XRPD pattern that includes a peak at about 20.32±0.2 degrees 2θ and a peak at about 21.36±0.2 degrees 2θ. In some embodiments, the compounds of the present invention exhibit an XRPD pattern that further includes a peak at about 18.86±0.2 degrees 2θ and a peak at about 13.15±0.2 degrees 2θ. In some embodiments, the compounds of the present invention exhibit an XRPD pattern that further includes a peak at about 18.47±0.2 degrees 2θ and a peak at about 20.05±0.2 degrees 2θ. In some embodiments, the compounds of the present invention exhibit an XRPD pattern that further includes a peak at about 22.22±0.2 degrees 2θ and a peak at about 23.24±0.2 degrees 2θ. In some embodiments, the compounds of the present invention exhibit an XRPD pattern that further includes a peak at about 16.70±0.2 degrees 2θ and a peak at about 21.70±0.2 degrees 2θ. In some embodiments, compounds of the present invention exhibit an XRPD pattern further comprising a peak at about 8.42±0.2 degrees 2θ and a peak at about 8.53±0.2 degrees 2θ.

[0105] In some embodiments, compounds of the invention exhibit an XRPD pattern that includes 1 peak, 2 peaks, 3 peaks, 4 peaks, 5 peaks, 6 peaks, 7 peaks, 8 peaks, 9 peaks or 10 peaks in Table 1. In some embodiments, the compounds of the invention exhibit an XRPD pattern that includes 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 of the following peaks: a peak at about 13.15±0.2 degrees 2θ, a peak at about 16.70±0.2 degrees 2θ, a peak at about 18.47±0.2 degrees 2θ, a peak at about 18.86±0.2 degrees 2θ, a peak at about 20.05±0.2 degrees 2θ, a peak at about 20.32±0.2 degrees 2θ, a peak at about 21.36±0.2 degrees 2θ, a peak at about 21.70±0.2 degrees 2θ, a peak at about 22.22±0.2 degrees 2θ, and a peak at about 23.24±0.2 degrees 2θ.

[0106] In some embodiments, compounds of the invention exhibit XRPD patterns that include peaks from Table 1 with a peak relative intensity (%) of greater than 70%. In some embodiments, compounds of the invention exhibit XRPD patterns that include peaks from Table 1 with a peak relative intensity (%) of greater than 50%. In some embodiments, compounds of the invention exhibit XRPD patterns that include peaks from Table 1 with a peak relative intensity (%) of greater than 30%.

[0107] In some embodiments, compounds of the invention exhibit an XRPD pattern that includes 1 peak, 2 peaks, 3 peaks, 4 peaks, 5 peaks, 6 peaks, 7 peaks, 8 peaks, 9 peaks or 10 peaks in Table 3.

[0108] In some embodiments, compounds of the present invention exhibit XRPD patterns substantially similar to those shown in FIG.

[0109] In some embodiments, compounds of the present invention do not exhibit XRPD patterns substantially similar to those shown in FIG.

[0110] In some embodiments, the compounds of the present invention comprise less than 5% phentolamine mesylate by weight of the compounds of the present invention exhibiting an XRPD pattern substantially similar to that shown in Figure 3. In some embodiments, the compounds of the present invention comprise less than 4% phentolamine mesylate by weight of the compounds of the present invention exhibiting an XRPD pattern substantially similar to that shown in Figure 3. In some embodiments, the compounds of the present invention comprise less than 2% phentolamine mesylate by weight of the compounds of the present invention exhibiting an XRPD pattern substantially similar to that shown in Figure 3. In some embodiments, the compounds of the present invention comprise less than 1% phentolamine mesylate by weight of the compounds of the present invention exhibiting an XRPD pattern substantially similar to that shown in Figure 3. In some embodiments, the compounds of the present invention comprise less than 0.5% phentolamine mesylate by weight of the compounds of the present invention exhibiting an XRPD pattern substantially similar to that shown in Figure 3.

[0111] In some embodiments, the compounds of the invention exhibit a differential scanning calorimetry (DSC) thermogram that includes an endothermic peak having a peak maximum at about 180° C. In some embodiments, the compounds of the invention exhibit a DSC thermogram that includes an endothermic peak with an onset at about 176° C.

[0112] In some embodiments, the compounds of the present invention exhibit a DSC thermogram that includes an endothermic peak having a peak maximum at about 120° C. In some embodiments, the compounds of the present invention exhibit a DSC thermogram that includes an endothermic peak with an onset at about 108° C.

[0113] In some embodiments, the compounds of the present invention exhibit a DSC thermogram that includes an endothermic peak with a peak maximum at about 133° C. In some embodiments, the compounds of the present invention exhibit a DSC thermogram that includes an endothermic peak with an onset at about 129° C.

[0114] In some embodiments, the compounds of the present invention exhibit a DSC thermogram comprising an endothermic peak having a peak maximum at about 120° C. and a peak maximum at about 180° C. In some embodiments, the compounds of the present invention exhibit a DSC thermogram comprising an endothermic peak with an onset at about 108° C. and an endothermic peak with an onset at about 176° C.

[0115] In some embodiments, the compounds of the present invention exhibit a DSC thermogram that includes an exothermic peak having a peak maximum between about 245°C and about 250°C.

[0116] In some embodiments, compounds of the present invention exhibit DSC thermograms substantially similar to those shown in FIG.

[0117] In some embodiments, compounds of the present invention exhibit a thermogravimetric (TG) thermogram substantially similar to that shown in FIG.

[0118] In some embodiments, compounds of the present invention do not exhibit a DSC thermogram substantially similar to that shown in FIG.

[0119] In some embodiments, compounds of the present invention do not exhibit a TG thermogram substantially similar to that shown in FIG.

[0120] In some embodiments, the compounds of the present invention contain less than about 20% amorphous phentolamine mesylate by weight or mole of the compound of the present invention. In some embodiments, the compounds of the present invention contain less than about 15% amorphous phentolamine mesylate by weight or mole of the compound of the present invention. In some embodiments, the compounds of the present invention contain less than about 10% amorphous phentolamine mesylate by weight or mole of the compound of the present invention. In some embodiments, the compounds of the present invention contain less than about 5% amorphous phentolamine mesylate by weight or mole of the compound of the present invention.

[0121] In some embodiments, the compounds of the present invention have a molar ratio of crystalline phentolamine mesylate to amorphous phentolamine mesylate of at least 4:1. In some embodiments, the compounds of the present invention have a molar ratio of crystalline phentolamine mesylate to amorphous phentolamine mesylate of at least 5:1. In some embodiments, the compounds of the present invention have a molar ratio of crystalline phentolamine mesylate to amorphous phentolamine mesylate of at least 17:3. In some embodiments, the compounds of the present invention have a molar ratio of crystalline phentolamine mesylate to amorphous phentolamine mesylate of at least 6:1. In some embodiments, the compounds of the present invention have a molar ratio of crystalline phentolamine mesylate to amorphous phentolamine mesylate of at least 7:1. In some embodiments, the compounds of the present invention have a molar ratio of crystalline phentolamine mesylate to amorphous phentolamine mesylate of at least 8:1. In some embodiments, the compounds of the present invention have a molar ratio of crystalline phentolamine mesylate to amorphous phentolamine mesylate of at least 9:1. In some embodiments, the compounds of the present invention have a molar ratio of crystalline phentolamine mesylate to amorphous phentolamine mesylate of at least 10:1. In some embodiments, the compounds of the present invention have a molar ratio of crystalline phentolamine mesylate to amorphous phentolamine mesylate of at least 11:1. In some embodiments, the compounds of the present invention have a molar ratio of crystalline phentolamine mesylate to amorphous phentolamine mesylate of at least 23:2. In some embodiments, the compounds of the present invention have a molar ratio of crystalline phentolamine mesylate to amorphous phentolamine mesylate of at least 12:1. In some embodiments, the compounds of the present invention have a molar ratio of crystalline phentolamine mesylate to amorphous phentolamine mesylate of at least 13:1. In some embodiments, the compounds of the present invention have a molar ratio of crystalline phentolamine mesylate to amorphous phentolamine mesylate of at least 93:7. In some embodiments, the compounds of the present invention have a molar ratio of crystalline phentolamine mesylate to amorphous phentolamine mesylate of at least 14:1.In some embodiments, the compounds of the present invention have a molar ratio of crystalline phentolamine mesylate to amorphous phentolamine mesylate of at least 15:1. In some embodiments, the compounds of the present invention have a molar ratio of crystalline phentolamine mesylate to amorphous phentolamine mesylate of at least 16:1. In some embodiments, the compounds of the present invention have a molar ratio of crystalline phentolamine mesylate to amorphous phentolamine mesylate of at least 17:1. In some embodiments, the compounds of the present invention have a molar ratio of crystalline phentolamine mesylate to amorphous phentolamine mesylate of at least 18:1. In some embodiments, the compounds of the present invention have a molar ratio of crystalline phentolamine mesylate to amorphous phentolamine mesylate of at least 19:1. In some embodiments, the compounds of the present invention have a molar ratio of crystalline phentolamine mesylate to amorphous phentolamine mesylate of at least 20:1.

[0122] The present invention further provides compounds of the present invention that are at least about 98% (by weight) of the compounds of the present invention, and the compounds of the present invention contain about 2% or less impurities (by weight) of the compounds of the present invention. In some embodiments, the purity of the compounds of the present invention is about 95.0%-100%, and the compounds of the present invention contain 0%-about 5% impurities by weight of the compounds of the present invention. In some embodiments, the purity of the compounds of the present invention is about 98%, about 98.5%, about 99%, about 99.5% or 100%, and the compounds of the present invention contain about 2%, about 1.5%, about 1%, about 0.5% or 0% impurities by weight of the compounds of the present invention, respectively, after drying. In some embodiments, the purity of the compounds of the present invention is about 99.5%, about 99.9%, or about 99.95%, and the compounds of the present invention contain about 0.5%, about 0.1%, or about 0.05% impurities by weight of the compounds of the present invention, respectively, after drying. In some embodiments, the purity of the compounds of the present invention is about 98%, about 98.5%, about 99%, about 99.5% or 100%, and the compounds of the present invention contain about 2%, about 1.5%, about 1%, about 0.5% or 0% impurities by weight of the compounds of the present invention, respectively, after drying on a rotary evaporator. In some embodiments, the purity of the compounds of the present invention is about 99.5%, about 99.9%, or about 99.95%, and the compounds of the present invention contain about 0.5%, about 0.1%, or about 0.05% impurities by weight of the compounds of the present invention, respectively, after drying on a rotary evaporator. In some embodiments, the purity of the compounds of the present invention is about 98%, about 98.5%, about 99%, about 99.5% or 100%, and the compounds of the present invention contain about 2%, about 1.5%, about 1%, about 0.5% or 0% impurities by weight of the compounds of the present invention, respectively, after lyophilization. In some embodiments, the impurities are determined by high performance liquid chromatography (HPLC). In some embodiments, the impurities are determined by titration.

[0123] In some embodiments, the compounds of the invention contain less than about 1% impurities by weight of the compound of the invention. In some embodiments, the compounds of the invention contain less than about 0.5% impurities by weight of the compound of the invention. In some embodiments, the compounds of the invention contain less than about 1%, less than about 0.9%, less than about 0.8%, less than about 0.7%, less than about 0.6%, less than about 0.5%, less than about 0.4%, less than about 0.3%, or less than about 0.2% impurities by weight of the compound of the invention.

[0124] In some embodiments, the purity determination of the compounds of the invention by HPLC involves comparing the compounds of the invention to a reference sample of phentolamine mesylate having a certified purity. In some embodiments, the purity of the compounds of the invention is determined by HPLC to be about 95% to about 102%, in some embodiments, about 95% to about 100%. In some embodiments, the purity of the compounds of the invention determined by HPLC takes into account only impurities that may be detected by the HPLC method used. In some embodiments, the purity of the compounds of the invention determined by HPLC does not take into account the presence of solvents, if any.

[0125] In some embodiments, the purity of the compounds of the invention is determined by HPLC using a mobile phase that is 0.5 g / L ammonium acetate in water:acetonitrile (67:33) solution. In some embodiments, the HPLC method used in determining the purity of the compounds of the invention includes using a detector set at about 220 nm to about 230 nm.

[0126] In some embodiments, the purity of the compounds of the invention is at least about 98%, and the compounds of the invention contain no more than about 2% impurities by chromatographic area of ​​the peak of the compound of the invention, as determined by gas chromatography (GC). In some embodiments, the purity of the compounds of the invention is about 95.0%-100%, and the compounds of the invention contain no more than 0% to about 5.0% impurities by chromatographic area of ​​the peak of the compound of the invention, as determined by GC. In some embodiments, the purity of the compounds of the invention is about 98%-100%, and the compounds of the invention contain no more than 0% to about 2% impurities by chromatographic area of ​​the peak of the compound of the invention, as determined by GC. In some embodiments, the GC method used in determining the purity of the compounds of the invention is the United States Pharmacopeia (USP) method. <467> In some embodiments, the compounds of the invention contain less than about 0.5% solvent as determined by GC. In some embodiments, the compounds of the invention contain less than about 0.3% solvent as determined by GC. In some embodiments, the compounds of the invention contain less than about 0.5% or less than about 0.3% solvent after drying as determined by GC. In some embodiments, the compounds of the invention contain less than about 0.5% or less than about 0.3% solvent after lyophilization as determined by GC.

[0127] In some embodiments, the compounds of the invention contain less than 1.5% impurities by weight of the compound of the invention. In some embodiments, the compounds of the invention contain less than 1% impurities by weight of the compound of the invention. In some embodiments, the compounds of the invention contain less than 0.5% impurities by weight of the compound of the invention. In some embodiments, the impurity is Compound 1. In some embodiments, the impurity is determined by high performance liquid chromatography (HPLC). In some embodiments, the impurity is determined by titration.

[0128] In some embodiments, the compounds of the present invention do not contain detectable amounts of alkyl methanesulfonates, hi some embodiments, the detectable amount is detectable by GC, HPLC or titration.

[0129] In some embodiments, the alkyl methanesulfonate is methyl methanesulfonate, ethyl methanesulfonate, n-propyl methanesulfonate, or isopropyl methanesulfonate.

[0130] In some embodiments, the compounds of the present invention contain less than about 8% water by weight as determined by Karl Fischer titration. In some embodiments, the compounds of the present invention contain less than about 6% water by weight of the compounds of the present invention as determined by Karl Fischer titration. In some embodiments, the compounds of the present invention contain less than about 2% water by weight as determined by Karl Fischer titration. In some embodiments, the compounds of the present invention contain less than about 1% water by weight of the compounds of the present invention as determined by Karl Fischer titration. In some embodiments, the compounds of the present invention contain less than about 0.5% water by weight of the compounds of the present invention as determined by Karl Fischer titration. In some embodiments, the compounds of the present invention contain less than about 8%, less than about 7.5%, less than about 7%, less than about 6.5%, less than about 6%, less than about 5.5%, less than about 5%, less than about 4.5%, less than about 4%, less than about 3.5%, less than about 3%, less than about 2.5%, less than about 2%, less than about 1.5%, less than about 1%, or less than about 0.5% water by weight of the compounds of the present invention as determined by Karl Fischer titration.

[0131] In some embodiments, the compounds of the invention contain, after drying, less than about 8% or less than about 6% water by weight of the compounds of the invention as determined by Karl Fischer titration. In some embodiments, the compounds of the invention contain, after drying on a rotary evaporator, less than about 8% or less than about 6% water by weight of the compounds of the invention as determined by Karl Fischer titration.

[0132] In some embodiments, the compounds of the invention contain, after drying, less than about 2% or less than about 1% water by weight of the compound of the invention as determined by Karl Fischer titration. In some embodiments, the compounds of the invention contain, after lyophilization, less than about 2% or less than about 1% water by weight of the compound of the invention as determined by Karl Fischer titration.

[0133] The present invention further provides a compound of the present invention obtained or obtainable as described in Example 1. In some embodiments, the compound of the present invention obtained or obtainable as described in Example 1 is crystalline phentolamine mesylate. In some embodiments, the compound of the present invention is greater than 99% pure without further purification.

[0134] The present invention further provides a compound of the present invention obtained or obtainable as described in Example 2. In some embodiments, the compound of the present invention obtained or obtainable as described in Example 2 is crystalline phentolamine mesylate. In some embodiments, the compound of the present invention is greater than 99% pure without further purification.

[0135] The invention further provides compounds of the invention made or makeable by the synthetic methods of the invention.

[0136] In some embodiments, the compounds of the present invention are free of impurities. In some embodiments, the compounds of the present invention are free of detectable amounts of impurities. In some embodiments, the isolated phentolamine mesylate, filtered phentolamine mesylate, or dried phentolamine mesylate are free of detectable amounts of impurities. In some embodiments, the compounds of the present invention are more than 99% pure without further purification. In some embodiments, the isolated phentolamine mesylate, filtered phentolamine mesylate, or dried phentolamine mesylate are more than 99% pure without further purification.

[0137] The present invention further provides phentolamine mesylate comprising less than 1% impurities by weight of phentolamine mesylate. In some embodiments, phentolamine mesylate comprises less than 0.5% impurities by weight of phentolamine mesylate. In some embodiments, phentolamine mesylate comprises less than 0.1% impurities by weight of phentolamine mesylate. In some embodiments, phentolamine mesylate comprises less than 1% impurities by weight of phentolamine mesylate, less than 0.9% impurities by weight, less than 0.8% impurities by weight, less than 0.7% impurities by weight, less than 0.6% impurities by weight, less than 0.5% impurities by weight, less than 0.4% impurities by weight, less than 0.3% impurities by weight, less than 0.2% impurities by weight, less than 0.1% impurities by weight, or less than 0.05% impurities by weight. In some embodiments, phentolamine mesylate is isolated phentolamine mesylate, filtered phentolamine mesylate, or dried phentolamine mesylate that is not subjected to further purification. In some embodiments, the phentolamine mesylate is dried phentolamine mesylate that is not subjected to further purification.

[0138] The present invention further provides phentolamine mesylate comprising water in the range of 0% by weight to about 6% by weight of phentolamine mesylate and less than 1% impurities by weight of phentolamine mesylate. In some embodiments, phentolamine mesylate comprises less than 0.5% impurities by weight of phentolamine mesylate. In some embodiments, phentolamine mesylate comprises less than 0.3% impurities by weight of phentolamine mesylate. In some embodiments, phentolamine mesylate comprises less than 0.1% impurities by weight of phentolamine mesylate. In some embodiments, phentolamine mesylate contains less than 1% impurities by weight of phentolamine mesylate, less than 0.9% impurities by weight, less than 0.8% impurities by weight, less than 0.7% impurities by weight, less than 0.6% impurities by weight, less than 0.5% impurities by weight, less than 0.4% impurities by weight, less than 0.3% impurities by weight, less than 0.2% impurities by weight, less than 0.1% impurities by weight, or less than 0.05% impurities by weight. In some embodiments, phentolamine mesylate contains 0% to about 3% water by weight of phentolamine mesylate. In some embodiments, phentolamine mesylate contains 0% to about 2% water by weight of phentolamine mesylate. In some embodiments, phentolamine mesylate contains 0% to about 1.5% water by weight of phentolamine mesylate. In some embodiments, phentolamine mesylate contains 0% to about 6% water by weight of phentolamine mesylate and contains less than 0.5% impurities by weight of phentolamine mesylate. In some embodiments, phentolamine mesylate contains 0% to about 6% water by weight of phentolamine mesylate and contains less than 0.3% impurities by weight of phentolamine mesylate. In some embodiments, phentolamine mesylate contains 0% to about 3% water by weight of phentolamine mesylate and contains less than 0.5% impurities by weight of phentolamine mesylate. In some embodiments, phentolamine mesylate contains 0% to about 2% water by weight of phentolamine mesylate and contains less than 0.5% impurities by weight of phentolamine mesylate.In some embodiments, phentolamine mesylate contains from 0% to about 2% water by weight of phentolamine mesylate and less than 0.1% impurities by weight of phentolamine mesylate.

[0139] In some embodiments, the impurity is Compound 1.

[0140] In some embodiments, the impurity is an alkyl methanesulfonate. In some embodiments of the compounds of the present invention, the alkyl methanesulfonate is methyl methanesulfonate, ethyl methanesulfonate, n-propyl methanesulfonate, or isopropyl methanesulfonate.

[0141] In some embodiments, the impurities are process by-products or decomposition products.

[0142] In some embodiments, the impurity is impurity A (N-(2-aminoethyl)-2-[(3-hydroxyphenyl)(4-methylphenyl)amino]-acetamide).

[0143] In some embodiments, the impurity is a salt of impurity A. In some embodiments, the impurity is a methanesulfonate salt of impurity A.

[0144] In some embodiments, impurity A is a process by-product or a degradation product.

[0145] In some embodiments, the impurity is impurity B (2-chloromethyl-4,5-dihydro-1H-imidazole). In some embodiments, the impurity is a salt of impurity B. In some embodiments, the impurity is a methanesulfonate salt of impurity B.

[0146] In some embodiments, impurity B is a process by-product or a decomposition product.

[0147] In some embodiments, the impurity is impurity C (3-hydroxy-4'-methyldiphenylamine). In some embodiments, the impurity is a salt of impurity C. In some embodiments, the impurity is a methanesulfonate salt of impurity C.

[0148] In some embodiments, impurity C is a process by-product. In some embodiments, impurity C is a degradation product.

[0149] In some embodiments, the impurity is one or more of impurity A, impurity B, and impurity C, or a salt thereof. In some embodiments, the salt is a methanesulfonate salt.

[0150] In some embodiments of the compounds of the present invention, the impurity is an alcohol solvent. In some embodiments of the compounds of the present invention, the alcohol solvent is methanol, ethanol, n-propanol, or isopropanol.

[0151] In some embodiments of the compounds of the present invention, the impurity is toluene.

[0152] In some embodiments of the compound of the present invention, the isolated phentolamine mesylate, filtered phentolamine mesylate, or dried phentolamine mesylate contains toluene in an amount of less than 890 ppm as determined by GC. In some embodiments of the compound of the present invention, the isolated phentolamine mesylate, filtered phentolamine mesylate, or dried phentolamine mesylate contains toluene in an amount of less than 5 ppm, less than 4 ppm, less than 3 ppm, less than 2 ppm, or less than 1 ppm as determined by GC. In some embodiments, the isolated phentolamine mesylate, filtered phentolamine mesylate, or dried phentolamine mesylate is free of toluene.

[0153] In some embodiments of the compounds of the present invention, the isolated phentolamine mesylate, filtered phentolamine mesylate, or dried phentolamine mesylate contains acetone in an amount less than 5000 ppm as determined by GC. In some embodiments, the isolated phentolamine mesylate, filtered phentolamine mesylate, or dried phentolamine mesylate contains acetone in an amount less than 1000 ppm, less than 900 ppm, less than 800 ppm, or less than 700 ppm as determined by GC.

[0154] In some embodiments of the compounds of the present invention, the isolated phentolamine mesylate, filtered phentolamine mesylate, or dried phentolamine mesylate contains ethyl acetate in an amount less than 5000 ppm as determined by GC. In some embodiments, the isolated phentolamine mesylate, filtered phentolamine mesylate, or dried phentolamine mesylate contains ethyl acetate in an amount less than 100 ppm, less than 90 ppm, less than 80 ppm, less than 70 ppm, less than 60 ppm, less than 50 ppm, less than 40 ppm, or less than 30 ppm as determined by GC.

[0155] In some embodiments of the compounds of the present invention, the isolated phentolamine mesylate, filtered phentolamine mesylate, or dried phentolamine mesylate contains methyl t-butyl ether in an amount less than 5000 ppm as determined by GC. In some embodiments, the isolated phentolamine mesylate, filtered phentolamine mesylate, or dried phentolamine mesylate contains methyl t-butyl ether in an amount less than 200 ppm, less than 180 ppm, less than 160 ppm, less than 140 ppm, less than 120 ppm, or less than 110 ppm as determined by GC.

[0156] In some embodiments of the compounds of the present invention, the impurity is water.

[0157] In some embodiments, the isolated phentolamine mesylate, filtered phentolamine mesylate, or dried phentolamine mesylate contains impurities that are 5% or less by weight of phentolamine mesylate.

[0158] In some embodiments, the isolated phentolamine mesylate, filtered phentolamine mesylate, or dried phentolamine mesylate contains impurities that are 4.5% or less, 4% or less, 3.5% or less, 3% or less, 2.5% or less, 2% or less, 1.5% or less, or 1% or less by weight of phentolamine mesylate.

[0159] In some embodiments, the impurity is Compound 1.

[0160] In some embodiments, the impurity is an alkyl methanesulfonate. In some embodiments of the compounds of the present invention, the alkyl methanesulfonate is methyl methanesulfonate, ethyl methanesulfonate, n-propyl methanesulfonate, or isopropyl methanesulfonate.

[0161] In some embodiments, the impurities are process by-products or decomposition products.

[0162] In some embodiments, the impurity is impurity A (N-(2-aminoethyl)-2-[(3-hydroxyphenyl)(4-methylphenyl)amino]-acetamide). In some embodiments, the impurity is a salt of impurity A. In some embodiments, the impurity is a methanesulfonate salt of impurity A.

[0163] In some embodiments, impurity A is a process by-product or a degradation product.

[0164] In some embodiments, the impurity is impurity B (2-chloromethyl-4,5-dihydro-1H-imidazole). In some embodiments, the impurity is a salt of impurity B. In some embodiments, the impurity is a methanesulfonate salt of impurity B. In some embodiments, impurity B is a process by-product or a degradation product.

[0165] In some embodiments, the impurity is impurity C (3-hydroxy-4'-methyldiphenylamine). In some embodiments, the impurity is a salt of impurity C. In some embodiments, the impurity is a methanesulfonate salt of impurity C. In some embodiments, impurity C is a process by-product. In some embodiments, impurity C is a degradation product.

[0166] In some embodiments, the impurity is one or more of impurity A, impurity B, and impurity C, or a salt thereof. In some embodiments, the salt is a methanesulfonate salt.

[0167] In some embodiments of the compounds of the present invention, the impurity is an alcohol solvent. In some embodiments of the compounds of the present invention, the alcohol solvent is methanol, ethanol, n-propanol, or isopropanol.

[0168] In some embodiments of the compounds of the present invention, the impurity is toluene.

[0169] In some embodiments of the compound of the present invention, the isolated phentolamine mesylate, filtered phentolamine mesylate, or dried phentolamine mesylate contains toluene in an amount of 890 ppm or less as determined by GC. In some embodiments of the compound of the present invention, the isolated phentolamine mesylate, filtered phentolamine mesylate, or dried phentolamine mesylate contains toluene in an amount of 5 ppm or less, 4 ppm or less, 3 ppm or less, 2 ppm or less, or 1 ppm or less as determined by GC.

[0170] In some embodiments of the compounds of the present invention, the isolated phentolamine mesylate, filtered phentolamine mesylate, or dried phentolamine mesylate contains acetone in an amount of 5000 ppm or less as determined by GC. In some embodiments, the isolated phentolamine mesylate, filtered phentolamine mesylate, or dried phentolamine mesylate contains acetone in an amount of 1000 ppm or less, 900 ppm or less, 800 ppm or less, or 700 ppm or less as determined by GC.

[0171] In some embodiments of the compounds of the present invention, the isolated phentolamine mesylate, filtered phentolamine mesylate, or dried phentolamine mesylate contains ethyl acetate in an amount of 5000 ppm or less as determined by GC. In some embodiments, the isolated phentolamine mesylate, filtered phentolamine mesylate, or dried phentolamine mesylate contains ethyl acetate in an amount of 100 ppm or less, 90 ppm or less, 80 ppm or less, 70 ppm or less, 60 ppm or less, 50 ppm or less, 40 ppm or less, or 30 ppm or less as determined by GC.

[0172] In some embodiments of the compounds of the present invention, the isolated phentolamine mesylate, filtered phentolamine mesylate, or dried phentolamine mesylate contains methyl t-butyl ether in an amount of 5000 ppm or less as determined by GC. In some embodiments, the isolated phentolamine mesylate, filtered phentolamine mesylate, or dried phentolamine mesylate contains methyl t-butyl ether in an amount of 200 ppm or less, 180 ppm or less, 160 ppm or less, 140 ppm or less, 120 ppm or less, or 110 ppm or less as determined by GC.

[0173] In some embodiments, the purity of the isolated phentolamine mesylate, filtered phentolamine mesylate, or dried phentolamine mesylate is at least about 98% (by weight) and contains impurities of about 2% or less by weight of phentolamine mesylate. In some embodiments, the purity or impurities are determined by high performance liquid chromatography (HPLC). In some embodiments, the impurities are determined by titration.

[0174] In some embodiments, the purity of the isolated phentolamine mesylate, filtered phentolamine mesylate, or dried phentolamine mesylate is about 95.0%-100% by weight, and the isolated phentolamine mesylate, filtered phentolamine mesylate, or dried phentolamine mesylate contains 0% to about 5.0% impurities by weight of phentolamine mesylate. In some embodiments, the purity of the isolated phentolamine mesylate, filtered phentolamine mesylate, or dried phentolamine mesylate is about 98%-100% by weight, and the isolated phentolamine mesylate, filtered phentolamine mesylate, or dried phentolamine mesylate contains 0% to about 2% impurities by weight of phentolamine mesylate. In some embodiments, the purity of the isolated phentolamine mesylate, filtered phentolamine mesylate, or dried phentolamine mesylate is about 98%, about 98.5%, about 99%, about 99.5%, or 100% by weight, and the isolated phentolamine mesylate, filtered phentolamine mesylate, or dried phentolamine mesylate contains about 2%, about 1.5%, about 1%, about 0.5%, or 0% impurities by weight of phentolamine mesylate, respectively. In some embodiments, the purity or impurities are determined by high performance liquid chromatography (HPLC). In some embodiments, the impurities are determined by titration.

[0175] In some embodiments of the compounds of the present invention, the purity of the isolated phentolamine mesylate, filtered phentolamine mesylate, or dried phentolamine mesylate is at least about 98%, and the isolated phentolamine mesylate, filtered phentolamine mesylate, or dried phentolamine mesylate contains no more than about 2% impurities by chromatographic area of ​​the peak of the compound of the present invention as determined by GC. In some embodiments, the purity of the isolated phentolamine mesylate, filtered phentolamine mesylate, or dried phentolamine mesylate is about 95.0% to 100%, and contains 0% to about 5.0% impurities by chromatographic area of ​​the peak of the compound of the present invention as determined by GC. In some embodiments, the purity of the isolated phentolamine mesylate, filtered phentolamine mesylate, or dried phentolamine mesylate is about 98% to 100%, and the isolated phentolamine mesylate, filtered phentolamine mesylate, or dried phentolamine mesylate contains 0% to about 2% impurities by chromatographic area of ​​the peak of the compound of the invention as determined by GC. In some embodiments, the purity of the isolated phentolamine mesylate, filtered phentolamine mesylate, or dried phentolamine mesylate is about 98%, about 98.5%, about 99%, about 99.5%, or 100%, and the isolated phentolamine mesylate, filtered phentolamine mesylate, or dried phentolamine mesylate contains about 2%, about 1.5%, about 1%, about 0.5%, or 0% impurities by chromatographic area of ​​the peak of the compound of the invention as determined by GC. In some embodiments, the isolated phentolamine mesylate, filtered phentolamine mesylate, or dried phentolamine mesylate contains less than about 0.5% solvent as determined by GC. In some embodiments, the isolated phentolamine mesylate, filtered phentolamine mesylate, or dried phentolamine mesylate contains less than about 0.3% solvent as determined by GC.

[0176] In some embodiments of the compounds of the invention, the isolated phentolamine mesylate, filtered phentolamine mesylate, or dried phentolamine mesylate contains less than 1.5% impurities by weight of the compounds of the invention. In some embodiments, the isolated phentolamine mesylate, filtered phentolamine mesylate, or dried phentolamine mesylate contains less than 1% impurities by weight of the compounds of the invention. In some embodiments, the isolated phentolamine mesylate, filtered phentolamine mesylate, or dried phentolamine mesylate contains less than 0.5% impurities by weight of the compounds of the invention. In some embodiments, the impurity is Compound 1. In some embodiments, the impurity is one or more of impurity A, impurity B, and impurity C, or salts thereof. In some embodiments, the salt is a methanesulfonate salt. In some embodiments, the impurities are determined by high performance liquid chromatography (HPLC). In some embodiments, the impurities are determined by titration.

[0177] In some embodiments of the compound of the present invention, the isolated phentolamine mesylate, filtered phentolamine mesylate, or dried phentolamine mesylate contains less than about 8% water by weight of the compound of the present invention as determined by Karl Fisher titration. In some embodiments, the isolated phentolamine mesylate, filtered phentolamine mesylate, or dried phentolamine mesylate contains less than about 6% water by weight of the compound of the present invention as determined by Karl Fisher titration. In some embodiments, the isolated phentolamine mesylate, filtered phentolamine mesylate, or dried phentolamine mesylate contains less than about 1% water by weight of the compound of the present invention as determined by Karl Fisher titration. In some embodiments, isolated phentolamine mesylate, filtered phentolamine mesylate, or dried phentolamine mesylate contains less than about 8%, less than about 7.5%, less than about 7%, less than about 6.5%, less than about 6%, less than about 5.5%, less than about 5%, less than about 4.5%, less than about 4%, less than about 3.5%, less than about 3%, less than about 2.5%, less than about 2%, less than about 1.5%, less than about 1%, or less than about 0.5% water by weight of the compound of the invention as determined by Karl Fischer titration.

[0178] In some embodiments, the invention provides compositions comprising a compound of the invention and an impurity, wherein the impurity is present in the composition in an amount of 0.5% or less by weight, moles, or volume of the composition. In some embodiments, the invention provides compositions comprising a compound of the invention and an impurity, wherein the impurity is present in the composition in an amount of 0.4% or less, 0.3% or less, 0.2% or less, or 0.1% or less of the mixture by weight, moles, or volume of the composition.

[0179] In some embodiments, the impurity is Compound 1.

[0180] In some embodiments, the impurity is an alkyl methanesulfonate. In some embodiments of the compounds of the present invention, the alkyl methanesulfonate is methyl methanesulfonate, ethyl methanesulfonate, n-propyl methanesulfonate, or isopropyl methanesulfonate.

[0181] In some embodiments, the impurities are process by-products or decomposition products.

[0182] In some embodiments, the impurity is impurity A (N-(2-aminoethyl)-2-[(3-hydroxyphenyl)(4-methylphenyl)amino]-acetamide). In some embodiments, the impurity is a salt of impurity A. In some embodiments, the impurity is a methanesulfonate salt of impurity A.

[0183] In some embodiments, impurity A is a by-product or a decomposition product.

[0184] In some embodiments, the impurity is impurity B (2-chloromethyl-4,5-dihydro-1H-imidazole). In some embodiments, impurity B is a process by-product. In some embodiments, the impurity is a salt of impurity B. In some embodiments, the impurity is a methanesulfonate salt of impurity B.

[0185] In some embodiments, the impurity is impurity C (3-hydroxy-4'-methyldiphenylamine). In some embodiments, impurity C is a process by-product or a degradation product. In some embodiments, impurity C is a degradation product. In some embodiments, the impurity is a salt of impurity C. In some embodiments, the impurity is a methanesulfonate salt of impurity C.

[0186] In some embodiments, the impurity is one or more of impurity A, impurity B, and impurity C, or a salt thereof. In some embodiments, the salt is a methanesulfonate salt.

[0187] In some embodiments of the compounds of the present invention, the impurity is an alcohol solvent. In some embodiments of the compounds of the present invention, the alcohol solvent is methanol, ethanol, n-propanol, or isopropanol.

[0188] In some embodiments of the compounds of the present invention, the impurity is toluene.

[0189] In some embodiments of the compounds of the present invention, the impurity is acetone, ethyl acetate or methyl t-butyl ether. In some embodiments, the impurity is water. In some embodiments of the compounds of the present invention, the impurity is a solvent.

[0190]

[0191] The invention further provides a sealed container containing a compound of the invention and an inert gas, hi some embodiments, the inert gas is argon or nitrogen.

[0192] The present invention further provides a sealed container containing isolated phentolamine mesylate and an inert gas, hi some embodiments, the inert gas is argon or nitrogen.

[0193] The present invention further provides a sealed container containing filtered phentolamine mesylate and an inert gas, hi some embodiments, the inert gas is argon or nitrogen.

[0194] The present invention further provides a sealed container containing dried phentolamine mesylate and an inert gas, hi some embodiments, the inert gas is argon or nitrogen.

[0195] Therapeutic Methods of the Invention

[0196] In some embodiments, the compounds of the present invention are useful for inhibiting iris smooth muscle contraction. Accordingly, the present invention further provides a method of inhibiting iris smooth muscle contraction, comprising administering to a subject in need thereof an effective amount of a compound of the present invention.

[0197] In some embodiments, the compounds of the present invention are useful for reducing pupil diameter. Accordingly, the present invention further provides a method of reducing pupil diameter, comprising administering to a subject in need thereof an effective amount of a compound of the present invention.

[0198] In some embodiments, the compounds of the invention are useful for improving visual contrast sensitivity or visual acuity. Accordingly, the invention further provides a method of improving visual contrast sensitivity or visual acuity, comprising administering to a subject in need thereof an effective amount of a compound of the invention.

[0199] In some embodiments, the compounds of the present invention are useful for treating impaired night vision or night vision. Accordingly, the present invention further provides a method for treating impaired night vision or night vision, comprising administering an effective amount of a compound of the present invention to a subject in need thereof.

[0200] In some embodiments, the compounds of the present invention are useful for treating or reversing pharmacologically induced mydriasis. Accordingly, the present invention further provides a method of treating or reversing pharmacologically induced mydriasis, comprising administering to a subject in need thereof an effective amount of a compound of the present invention.

[0201] In some embodiments, the compounds of the present invention are useful for treating presbyopia. Accordingly, the present invention further provides a method of treating presbyopia, comprising administering to a subject in need thereof an effective amount of a compound of the present invention.

[0202] In some embodiments, administration is by topical instillation into the subject's eye.

[0203] In some embodiments, the effective amount of the compound of the present invention is about 0.01 mg to about 100 mg. In some embodiments, the effective amount of the compound of the present invention is about 0.05 mg to about 50 mg. In some embodiments, the effective amount of the compound of the present invention is about 0.1 mg to about 100 mg. In some embodiments, the effective amount of the compound of the present invention is about 1 mg to about 25 mg. In some embodiments, the effective amount of the compound of the present invention is about 5 mg to about 10 mg.

[0204] In some embodiments, the effective amount of the compound of the invention is about 0.1 mg to about 2.0 mg, about 0.2 mg to about 0.7 mg, about 0.4 mg to about 0.6 mg, or about 0.8 mg to about 1.2 mg, hi some embodiments, the effective amount of the compound of the invention is about 0.5 mg or about 1 mg.

[0205] In some embodiments, the effective amount of the compound of the present invention is about 0.1 mg to about 2.0 mg. In some embodiments, the effective amount of the compound of the present invention is about 0.1 mg to about 1.0 mg. In some embodiments, the effective amount of the compound of the present invention is about 0.2 mg to about 0.7 mg. In some embodiments, the effective amount of the compound of the present invention is about 0.4 mg to about 0.6 mg. In some embodiments, the effective amount of the compound of the present invention is about 0.25 mg, about 0.5 mg, or about 1.0 mg. In some embodiments, the effective amount of the compound of the present invention is about 0.5 mg.

[0206] Pharmaceutical Compositions

[0207] In some embodiments, the compound of the present invention is present in a composition. In some embodiments, the composition is a pharmaceutical composition. In some embodiments, the composition comprises a compound of the present invention and a pharma- ceutically acceptable carrier or excipient.

[0208] In some embodiments, the composition is formulated for administration by various means, including oral, parenteral, inhalation spray, topical, or rectal. The term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular, and intraarterial injections using various injection techniques. Intraarterial and intravenous injections as used herein include administration via catheter.

[0209] In some embodiments, the composition is a solution, suspension, emulsion, tablet, pill, capsule, powder, cream, or gel.

[0210] In some embodiments, the pharmaceutical composition is an ophthalmic solution. In some embodiments, the ophthalmic solution comprises about 0.5% to about 2% of a compound of the present invention by weight of the ophthalmic solution. In some embodiments, the ophthalmic solution comprises an amount of a compound of the present invention that is about 0.5% to about 5% molar equivalent of compound 1 by weight or volume of the ophthalmic solution. In some embodiments, the ophthalmic solution comprises an amount of a compound of the present invention that is about 0.35% or about 1% molar equivalent of compound 1 by weight or volume of the ophthalmic solution. In some embodiments, the ophthalmic solution comprises an amount of a compound of the present invention that is about 0.37% or about 0.5% molar equivalent of compound 1 by weight or volume of the ophthalmic solution. In some embodiments, the ophthalmic solution comprises an amount of a compound of the present invention that is about 0.35% or about 0.75% by weight or volume of the ophthalmic composition.

[0211] In some embodiments, the composition comprises about 1% phentolamine mesylate by weight of the composition. In some embodiments, the composition comprises about 1% phentolamine mesylate by volume of the composition. In some embodiments, the composition is an ophthalmic composition.

[0212] In some embodiments, the composition comprises about 0.5% phentolamine mesylate by weight of the composition. In some embodiments, the composition comprises about 0.5% phentolamine mesylate by volume of the composition. In some embodiments, the composition is an ophthalmic composition.

[0213] In some embodiments, the eye drops are suitable for ocular administration or ophthalmic use, hi some embodiments, the eye drops are suitable for topical, subconjunctival, intravitreal, retrobulbar, intracameral or systemic administration.

[0214] In some embodiments, the pharma- ceutically acceptable carrier or vehicle is a stabilizer, binder, filler, diluent, disintegrant, wetting agent, lubricant, glidant, colorant, dye transfer inhibitor, sweetener, flavoring agent, viscosity modifier, pH adjuster, buffer, osmotic agent, chelating agent, surfactant, or cosolvent.

[0215] In some embodiments, the viscosity modifier is polyvinyl alcohol, poloxamer, hyaluronic acid, carbomer, and polysaccharides, i.e., cellulose derivatives, gellan gum, or xanthan gum.

[0216] In some embodiments, the pharma- ceutically acceptable carrier or vehicle is sterile water, a sterile buffer solution or a sterile saline solution.

[0217] In some embodiments, the pharma- ceutically acceptable carrier or vehicle comprises or is mannitol or sodium acetate.

[0218] In some embodiments, the compositions of the present invention include a preservative, which in some embodiments is benzalkonium chloride, cetrimide, polyquaternium-1, thimerosal, sodium perborate, stabilized oxychloro complexes, stabilized chlorite peroxide, chlorhexidine, chlorobutanol, phenylethanol, or methylparaben.

[0219] In some embodiments, the compositions of the present invention do not include a preservative. In some embodiments, the compositions of the present invention do not include a preservative.

[0220] In some embodiments, the compositions of the present invention have a pH in the range of about 4 to about 6. In some embodiments, the compositions of the present invention have a pH in the range of about 4.5 to about 5.3. In some embodiments, the compositions have a pH of about 4.5, about 4.6, about 4.7, about 4.8, about 4.9, about 5.0, about 5.1, about 5.2, or about 5.3.

[0221] In some embodiments, the compositions of the present invention are contained in a sealed container. In some embodiments, the sealed container further comprises an inert gas. In some embodiments, the inert gas is argon or nitrogen.

[0222] In some embodiments, the compositions of the present invention are useful for inhibiting iris smooth muscle contraction. Accordingly, the present invention further provides a method of inhibiting iris smooth muscle contraction, comprising administering to a subject in need thereof an effective amount of a composition of the present invention.

[0223] In some embodiments, the compositions of the invention are useful for reducing pupil diameter. Accordingly, the invention further provides a method of reducing pupil diameter, comprising administering to a subject in need thereof an effective amount of a composition of the invention.

[0224] In some embodiments, the compositions of the present invention are useful for improving visual contrast sensitivity or visual acuity. Accordingly, the present invention further provides a method of improving visual contrast sensitivity or visual acuity, comprising administering to a subject in need thereof an effective amount of a composition of the present invention.

[0225] In some embodiments, the compositions of the present invention are useful for treating impaired night vision or night vision. Accordingly, the present invention further provides a method of treating impaired night vision or night vision, comprising administering an effective amount of a composition of the present invention to a subject in need thereof.

[0226] In some embodiments, the compositions of the present invention are useful for treating or reversing pharmacologically induced mydriasis. Accordingly, the present invention further provides a method of treating or reversing pharmacologically induced mydriasis, comprising administering to a subject in need thereof an effective amount of a composition of the present invention.

[0227] In some embodiments, the compositions of the present invention are useful for treating presbyopia. Accordingly, the present invention further provides a method of treating presbyopia, comprising administering to a subject in need thereof an effective amount of a composition of the present invention.

[0228] In some embodiments, administration is by topical instillation into the subject's eye. EXAMPLES

[0229] Example 1. Synthesis of phentolamine mesylate from compound 1 [ka]

[0230] To a suspension of 3-[[(4,5-dihydro-1H-imidazol-2-yl)methyl](4-methylphenyl)amino]phenol (compound 1; 145 g, 515.35 mmol) in a mixture of acetone (1560 mL) and water (134 mL) was added methanesulfonic acid (54.5 g, 567 mmol, 1.1 equiv.) over a period of 20 min under an argon atmosphere. The temperature of the reaction mixture spontaneously increased from 20° C. to 29.4° C. The reaction mixture became a clear solution and the reaction mixture was kept stirring at room temperature for 0.5 h. Methyl t-butyl ether (MTBE; 1450 mL) was added to the reaction mixture. The resulting mixture was cooled to 0±3° C. at a rate of about 1.33° C. / min for about 15 min. Upon reaching a temperature of about 11° C., phentolamine mesylate began to precipitate from the mixture. After reaching 0±3° C., the mixture was maintained at this temperature for 1 h, further cooled to −20±3° C. at a rate of about 1° C. / min for about 20 min, and maintained at −20±3° C. with stirring for 3 h. The precipitate was collected by vacuum filtration, washed with MTBE (435 mL), dried on a 1-L rotary evaporator at 43° C. under reduced pressure (40 mbar) for 48 h, and further dried by lyophilization to give 3-[[(4,5-dihydro-1H-imidazol-2-yl)methyl](4-methylphenyl)amino]phenol mesylate (phentolamine mesylate; 171 g, yield: 87.9%) as a white solid. HPLC: 99.95%. 1 H NMR (300 MHz, DMSO-d 6 / TMS): δ 9.99 (s, 2H), 9.31 (s, 1H), 7.18 (d, J = 8.1 Hz, 2H), 7.08 (d, J = 8.1 Hz, 2H), 7.02 (t, J = 8.1 Hz, 1H), 6.33 (dd, J = 7.2 Hz, J = 1.8 Hz, 1H), 6.24 (dd, J = 7.2 Hz, J = 1.8 Hz, 1H), 6.20 (s, 1H), 4.73 (s, 2H), 3.81 (s, 4H), 2.30 (s, 3H), 2.27 (s, 3H). 13 C NMR (75 MHz, DMSO-d 6 / TMS): δ 170.2, 158.6, 149.2, 144.5, 133.9, 130.5, 130.3, 124.3, 108.7, 108.6, 105.4, 49.3, 44.9, 20.8.

[0231] Example 2. Synthesis of phentolamine mesylate from compound 1

[0232] To a suspension of 3-[[(4,5-dihydro-1H-imidazol-2-yl)methyl](4-methylphenyl)amino]phenol (compound 1; 828 g, 2.91 mmol) in a mixture of acetone (8900 mL) and water (765 mL), methanesulfonic acid (311 g, 3.21 mol, 1.1 equiv.) was added over 30 min under argon atmosphere. The temperature of the reaction mixture spontaneously increased from 15.7 °C to 26 °C. The reaction mixture became clear and the reaction mixture was kept stirring at room temperature for 0.5 h. MTBE (8280 mL) was added to the above reaction mixture. The resulting mixture was cooled to 0 ± 3 °C at a rate of about 1.33 °C / min for about 15 min. Upon reaching a temperature of about 11 °C, phentolamine mesylate started to precipitate from the mixture. After reaching 0±3° C., the mixture was maintained at this temperature for 1 h, further cooled to −20±3° C. at a rate of about 1° C. / min for about 20 min, and maintained at −20±3° C. with stirring for 3 h. The resulting precipitate was collected by vacuum filtration, washed with MTBE (1240 mL×2), and dried using a 10-L rotary evaporator at 43° C. under reduced pressure (40 mbar) for 5 h and then at 6 mbar for 5 h to give 3-[[(4,5-dihydro-1H-imidazol-2-yl)methyl](4-methylphenyl)amino]phenol mesylate (phentolamine mesylate; 956.2 g, yield: 86.6%) as an off-white solid. HPLC: 99.55%. 1 H NMR (300 MHz, DMSO-d 6 / TMS): δ 9.99 (s, 2H), 9.31 (s, 1H), 7.18 (d, J = 8.1 Hz, 2H), 7.08 (d, J = 8.1 Hz, 2H), 7.02 (t, J = 8.1 Hz, 1H), 6.33 (dd, J = 7.2 Hz, J 13C NMR (75 MHz, DMSO-d 6 / TMS): δ 170.2, 158.6, 149.2, 144.5, 133.9, 130.5, 130.3, 124.3, 108.7, 108.6, 105.4, 49.3, 44.9, 20.8.

[0233] X-ray powder diffraction (XRPD) analysis was performed using a Bruker D8 Discover diffractometer with DAVINCI configuration in transmission mode (scan type: 2θ or offset combined 2θ / θ) scanning approximately 5 mg of phentolamine mesylate obtained according to Example 2 from 1.5 to 45° 2θ angles, with the following measurement characteristics: acquisition time was 53 min, increment per step was 0.01°, time per step was 0.7 s, generator voltage / generator amperage was 40 mA / 40 kV, reaching a power of 1.6 kW.

[0234] The raw data was imported into Diffrac.EVA5.0 software and processed using the following parameters: background subtraction and Kα2 stripping were performed before peak determination, and peak search operation was performed with a sample threshold of 1 and a peak width of 0.153. Only the obtained peaks with a relative intensity above 2% were considered. The crystallinity was calculated using Diffrac.EVA5.0 software option. The crystallinity of phentolamine mesylate obtained in Example 2 was 91.5% and the amorphous phase was 8.5%, indicating that the material has a high crystallinity.

[0235] FIG. 1 shows the XRPD diffractogram of phentolamine mesylate obtained as described in Example 2, and Table 1 shows the XRPD peaks represented in FIG.

[0236] [Table 1-1] [Table 1-2]

[0237] Thermogravimetry (TG) / Differential Scanning Calorimetry (DSC) analysis was performed. A sample of phentolamine mesylate (approximately 9 mg) obtained according to Example 2 was weighed into an open aluminum pan and loaded into a simultaneous Setarum LABSYS EVO Thermogravimetry / Differential Scanning Calorimetry (TG-DTA / DSC) and maintained at 30° C. for 15 minutes. The sample was then heated from 30° C. to 550° C. during which the change in sample weight was recorded along with any differential thermal events. Nitrogen was blown at 180 cm 3 1000 ppm was used as the purge gas at a flow rate of 1000 ppm / min. Prior to the analysis, the mass loss and temperature of the instrument were calibrated using copper sulfate pentahydrate and reference standards (lead and indium), respectively. Sample analysis was performed with the aid of CALISTO software, and the corresponding mass loss and temperature of the thermal event were quoted as the measured onset temperature according to the manufacturer's specifications. The analysis was performed at a heating rate of 10 °C / min, and background was subtracted before further processing.

[0238] TG / DSC analysis showed three endothermic events (peak maxima at about 120° C., 133° C., and about 180° C.) and one exothermic event (FIG. 2).

[0239] The TG / DSC analysis did not show any thermal events that would indicate or suggest that the sample had lost water.

[0240] Example 3. Comparison of Powder XRPD Patterns and TG / DSC Thermograms

[0241] XRPD and TG / DSC analyses of commercially available United States Pharmacopeia (USP) reference standard phentolamine mesylate (purity: 99.5%) were performed as described in Example 2. The XRPD pattern and TG / DSC thermogram of the phentolamine mesylate USP reference standard were compared with those of phentolamine mesylate obtained according to Example 2.

[0242] The crystallinity of the phentolamine mesylate USP reference standard was 85.1% with 14.9% amorphous phase, compared to the phentolamine mesylate obtained according to Example 2 (which had 91.5% crystallinity and 8.5% amorphous phase).

[0243] FIG. 3 shows the XRPD diffractogram of phentolamine mesylate USP reference standard and Table 2 shows the XRPD peaks represented in FIG.

[0244] [Table 2-1] [Table 2-2]

[0245] Table 3 shows selected peaks of the XRPD pattern of phentolamine mesylate obtained according to Example 2.

[0246] [Table 3]

[0247] TG / DSC analysis showed one endothermic event (peak maximum at about 183° C.) and one exothermic event (FIG. 4).

[0248] Based on the TG / DSC data, both phentolamine mesylate obtained according to Example 2 and phentolamine mesylate USP reference standard are anhydrous.

Claims

1. A method for preparing fenfluramine mesylate, comprising: (a) reacting compound 1 【Chemical Formula 7】 with methanesulfonic acid under conditions effective to produce a first mixture containing fenfluramine mesylate in the presence of acetone and water; (b) mixing the first mixture with methyl t-butyl ether to produce a second mixture; and (c) precipitating the fenfluramine mesylate from the second mixture.

2. The method according to claim 1, wherein the step of precipitating the fenfluramine mesylate from the second mixture comprises cooling the second mixture to a temperature of about 15°C to about -25°C.

3. The method according to claim 1, further comprising: (d) isolating the fenfluramine mesylate from the second mixture, the isolating step providing isolated fenfluramine mesylate, and optionally, the isolating step being a filtering step and the isolated fenfluramine mesylate being filtered fenfluramine mesylate.

4. The method according to claim 3, further comprising: (e) drying the isolated fenfluramine mesylate to provide dried fenfluramine mesylate.

5. The method according to claim 1, wherein the acetone and water are present in the first mixture of step (a) in a volume ratio of acetone:water of about 10:1 to about 12:

1.

6. The method according to claim 1, wherein compound 1 is present in the first mixture of step (a) at a concentration of about 0.2 mol / liter to about 0.4 mol / liter of the acetone and water.

7. The method according to claim 1, comprising reacting 1 molar equivalent of compound 1 with about 1.1 molar equivalents of methanesulfonic acid.

8. (i) the dried fenfluramine mesylate has a purity of at least about 98% by weight of the dried fenfluramine mesylate; and / or (ii) The dried phentermine mesylate contains less than 0.5% impurities by weight of the dried phentermine mesylate, and optionally the impurities are compound 1, alkyl methanesulfonate, or N-(2-aminoethyl)-2-[(3-hydroxyphenyl)(4-methylphenyl)amino]-acetamide, 2-chloromethyl-4,5-dihydro-1H-imidazole or 3-hydroxy-4'-methyldiphenylamine or a salt thereof, the method according to claim 4.

9. The method according to any one of claims 1 to 8, wherein (i) the method is carried out in the absence of a detectable amount of an alcohol solvent and / or (ii) the method is carried out in the absence of a detectable amount of toluene.

10. The method according to claim 4, wherein the dried phentermine mesylate does not undergo further purification.

11. Phentermine mesylate showing an X-ray powder diffraction (XRPD) pattern comprising peaks at 2θ of about 6.87 ± 0.2 degrees, about 20.32 ± 0.2 degrees, about 21.36 ± 0.2 degrees, about 18.86 ± 0.2 degrees, about 21.07 ± 0.2 degrees, about 11.65 ± 0.2 degrees, about 13.15 ± 0.2 degrees, and about 20.85 ± 0.2 degrees.

12. The phentermine mesylate according to claim 11, wherein the phentermine mesylate contains less than 6% water by weight of the phentermine mesylate determined by Karl Fischer titration.

13. The phentermine mesylate according to claim 11 or 12, wherein the phentermine mesylate contains less than 1% impurities by weight of the phentermine mesylate.

14. The impurities are: (i) compound 1, (ii) alkyl methanesulfonate, or (iii) N-(2-aminoethyl)-2-[(3-hydroxyphenyl)(4-methylphenyl)amino]-acetamide, 2-chloromethyl-4,5-dihydro-1H-imidazole, or 3-hydroxy-4'-methyldiphenylamine, or a salt thereof the phentermine mesylate according to claim 13.

15. The fenfluramine mesylate according to claim 12, wherein the fenfluramine mesylate contains amorphous fenfluramine mesylate in an amount of less than 10% by weight of the fenfluramine mesylate.

16. The fenfluramine mesylate according to claim 14, wherein the fenfluramine mesylate contains amorphous fenfluramine mesylate in an amount of less than 10% by weight of the fenfluramine mesylate.

17. A composition comprising an effective amount of the fenfluramine mesylate according to claim 13 and a pharmaceutically acceptable carrier or excipient.

18. A composition comprising an effective amount of the fenfluramine mesylate according to claim 16 and a pharmaceutically acceptable carrier or excipient.

19.

20. The composition according to claim 17, wherein the composition is an eye drop.

21.

22. The composition according to claim 19, wherein the composition contains the fenfluramine mesylate in an amount of about 0.5% to about 2% by weight or volume of the composition.

Images